A Phase 2 interventional study of HR18042 and HR18042 in Moderate to Severe Acute Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Acute Pain with a site in China — 8 open to participants now, 9 under way, none of them phase 3. Acute Pain · China.
Among the 23 studies in Acute Pain with a site in China, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2, and was the 7th registered.
1,076 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →8 of the 23 studies in Acute Pain with a site in China are open now. Recruiting first, the newest first:
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–80 · Healthy volunteers
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–70
Chinese PLA General Hospital · Sites in China
Ages up to 17
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 86 across 904 interventional studies indexed under Acute Pain.
Median enrollment 152 across the 18 interventional studies, 600 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 2 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07606911Shanghai Jiao Tong University Affiliated Sixth People's HospitalEffect of Liposomal Bupivacaine on Rebound Pain After Peripheral Nerve Block in Orthopedic Surgery. | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Acute Pain with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the Efficacy and safety of HR18042 tablets for the Treatment of Post-surgical Pain After extraction of impacted tooth, find the optimal dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HR18042
Drug: HR18042
Drug: HR18042
Drug: Tramadol hydrochloride ER
Drug: Placebo
Tablet, Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
the Sum of Pain Intensity Differences(SPID)
SPID is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.
Time frame: 0-8hours
the Sum of Pain Intensity Differences(SPID)
Time frame: 0-4hours
the Sum of Pain Intensity Differences(SPID)
Time frame: 0-12hours
Pain Intensity Differences(PID)
Include pain intensity differences(PIDs) from baseline at each time point. measured at different time points via the PI-VAS.
Time frame: 0-12hours
Pain relief(PAR)
pain relief (PAR) on a 5-point Likert scale (0, none, 1, a little, 2, some,3, a lot, 4, complete).
Time frame: 0-12hours
the Sum of Pain relief Differences(SPAR)
SPAR is derived as the weighted Sum of Pain relief, measured at different time points via the 5-point Likert scale. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.
Time frame: 0-4hours
the Sum of Pain relief Differences(SPAR)
Time frame: 0-8hours
the Sum of Pain relief Differences(SPAR).
Time frame: 0-12hours
Subject who reaches a 30% reduction in pain intensity from baseline
Time frame: 4hours、8hours、12hours
Subject who reaches a 50% reduction in pain intensity from baseline
Time frame: 4hours、8hours、12hours
time to perceptible pain relief
Time frame: 0-12hours
time to meaningful pain relief
Patients used one stopwatch to record the time to 'perceptible' PAR and another stopwatch for the time to'meaningful' PAR.Patients started timing upon intake of study medication and stopped one stopwatch at the onset of perceptible PAR and another upon achieving meaningful PAR.
Time frame: 0-12hours
Time to first use of rescue medication
Time frame: 0-12hours
Proportion of subjects who take of at least 1 dose of rescue medication
Time frame: 0-12hours
Subject's overall assessment of study medication
Patients made an overall assessment of the study medication using a verbal rating scale (excellent, verygood, good, fair, poor).
Time frame: 12hours
Ran from Dec 2020 to primary completion in Jan 2021, 1 month.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu HengRui Medicine Co., Ltd. →